Dr. Anjali Vaidya Provides Perspective to Healio on FDA Filing Acceptance of New Drug Application for Ralinepag for Treatment of Pulmonary Arterial Hypertension

Anjali Vaidya, MD, FACC, FASE, FACP, Director of the Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program at Temple University Hospital, provided perspective for a Healio article on the U.S. Food and Drug Administration (FDA) filing acceptance of a new drug application for ralinepag, a once-daily oral prostacyclin for the treatment of pulmonary arterial hypertension (PAH).